Lukang Pharmaceutical announced that the company recently received a “Drug Registration Certificate” for dagliflizine metformin extended-release tablets issued by the State Drug Administration. The compound formulation is suitable for adults with type 2 diabetes. It was launched domestically in June 2023, and 17 domestic companies have now been approved as generic drugs according to the new registration classification. Domestic sales for the first quarter of 2025 and 2026 were 615 million yuan and 271 million yuan, respectively. As of the announcement disclosure date, the company invested about 8.88 million yuan in research and development of the drug. Drug sales are affected by a variety of factors, and there is uncertainty.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.